Locally advanced and metastatic prostate cancer treated with intermittent androgen monotherapy or maximal androgen blockade: Results from a randomised phase 3 study by the south european uroncological group

European Urology

Volumn 66, Issue 2, 2014, Pages 232-239

  Silva, Fernando Calais Da ^a   Silva, Fernando Manuel Calais Da ^a   Gonçalves, Frederico ^b   Santos, Américo ^c   Kliment, Jan ^d   Whelan, Peter ^e   Oliver, Tim ^f   Antoniou, Nicos ^g   Pastidis, Spiro ^h   Marques Queimadelos, Anton ^h   Robertson, Chris ^i,j,k  

^a Centro Hospitalar Lisboa Central   (Portugal)

^b DFNsP   (Slovakia)

^c HOSPITAL DE BRAGA   (Portugal)

^d Jessenius School of Medicine   (Slovakia)

^e ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^f ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

^g Amalia Fleming Hospital   (Greece)

^h Department of Urology   (Spain)

ⁱ UNIVERSITY OF STRATHCLYDE   (United Kingdom)

^j HEALTH PROTECTION SCOTLAND   (United Kingdom)

^k INTERNATIONAL PREVENTION RESEARCH INSTITUTE   (France)

more..

Author keywords

Intermittent antiandrogen therapy; Maximal androgen blockade; Prostate cancer

Indexed keywords

CYPROTERONE ACETATE; PROSTATE SPECIFIC ANTIGEN; TRIPTORELIN; ANTINEOPLASTIC AGENT;

ADVANCED CANCER; AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; BONE SCINTISCANNING; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER SURVIVAL; CAUSE OF DEATH; CAUSE SPECIFIC SURVIVAL; CEREBROVASCULAR ACCIDENT; CHRONIC DISEASE; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DISEASE SEVERITY; DRUG INDUCED HEADACHE; DRUG INTERMITTENT THERAPY; DRUG SAFETY; GLEASON SCORE; GROUPS BY AGE; GYNECOMASTIA; HEART INFARCTION; HOT FLUSH; HUMAN; INDUCTION CHEMOTHERAPY; MAJOR CLINICAL STUDY; MALE; METASTASIS; MONOTHERAPY; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSTATE BIOPSY; PROSTATE CANCER; QUALITY OF LIFE; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE; SEXUAL BEHAVIOR; SEXUAL FUNCTION; SKIN DISEASE; TREATMENT OUTCOME; TREATMENT RESPONSE; WATCHFUL WAITING; ADENOCARCINOMA; BLOOD; CLINICAL TRIAL; COMPARATIVE STUDY; DISEASE COURSE; EUROPE; MIDDLE AGED; PATHOLOGY; PROSTATIC NEOPLASMS; SECONDARY; SEXUALITY; SURVIVAL RATE; TIME; VERY ELDERLY;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYPROTERONE ACETATE; DISEASE PROGRESSION; EUROPE; HUMANS; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; QUALITY OF LIFE; SEXUALITY; SURVIVAL RATE; TIME FACTORS; TRIPTORELIN PAMOATE;

EID: 84904062902     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2013.03.055     Document Type: Article

References (16)

1. Heidenreich A, Bastian PJ, Bellmunt J, et al. Guidelines on prostate cancer. European Association of Urology Web site. http://www.uroweb.org/gls/pdf/ 08%20Prostate%20Cancer-LR%20March%2013th%202012.pdf.
2. F.E. Calais da Silva, A.V. Bono, and P. Whelan et al. Intermittent androgen deprivation for locally advanced and metastatic prostate cancer: results from a randomised phase 3 study of the South European Uroncological Group Eur Urol 55 2009 1269 1277
3. M. Hussain, C.M. Tangen, and C.S. Higano et al. Intermittent (IAD) versus continuous androgen deprivation (CAD) in hormone sensitive metastatic prostate cancer (HSM1PC) patients (pts): results of S9346 (INT-0162), an international phase III trial [abstract 4] J Clin Oncol 30 2012
4. K. Miller, U. Steiner, and A. Lingnau et al. Randomised prospective study of intermittent versus continuous androgen suppression in advanced prostate cancer [abstract 5015] J Clin Oncol 25 2007
5. U. Tunn, R. Kurek, E. Kienle, and L. Maubach Intermittent is as effective as continuous androgen deprivation in patients with PSA-relapse after radical prostatectomy (RP) [abstract 1458] J Urol 171 2004
6. P.A. Abrahamsson Potential benefits of intermittent androgen suppression therapy in the treatment of prostate cancer: a systematic review of the literature Eur Urol 57 2010 49 59
7. N. Bruchovsky, P.S. Rennie, A.J. Coldman, S.L. Goldenberg, M. To, and D. Lawson Effects of androgen withdrawal on the stem cell composition of the Shionogi carcinoma Cancer Res 50 1990 2275 2282
8. M. Crook, C.J. O'Callaghan, and K. Ding et al. A phase III randomized trial of intermittent versus continuous androgen suppression for PSA progression after radical therapy (NCIC CTG PR.7/SWOG JPR.7/CTSU JPR.7/UK Intercontinental Trial CRUKE/01/013) [abstract 4514] J Clin Oncol 29 Suppl 2011
9. R.J. Gray A class of K-sample tests for comparing the cumulative incidence of a competing risk Ann Statistics 16 1988 1141 1154
10. J.P. Fine, and R.J. Gray A proportional hazards model for the subdistribution of a competing risk J Am Stat Assoc 94 1999 496 509
11. B. Seruga, and I.F. Tannock Intermittent androgen blockade should be regarded as standard therapy in prostate cancer Nat Clin Pract Oncol 5 2008 574 576
12. G.L. Shaw, P. Wilson, and J. Cuzick et al. International study into the use of intermittent hormone therapy in the treatment of carcinoma of the prostate: a meta-analysis of 1446 patients BJU Int 99 2007 1056 1065
13. A. De la Taille, M. Zerbib, and S. Conquy Intermittent androgen suppression in patients with prostate cancer BJU Int 91 2002 18 22
14. J. Irani, O. Celhay, and J. Hubert et al. Continuous versus six months a year maximal androgen blockade in the management of prostate cancer: a randomised study Eur Urol 54 2008 382 391
15. J.F. Langenhuijsen, D. Badhauser, B. Schaaf, L.A. Kiemeney, J.A. Witjes, and P.F. Mulders Continuous vs. intermittent androgen deprivation therapy for metastatic prostate cancer Urol Oncol 31 2013 549 556
16. Y. Benjamini, and Y. Hochberg Controlling the false discovery rate: a practical and powerful approach to multiple testing J Royal Stat Soc B 57 1995 289 300